No strategy for pregnant women with glaucoma

Article

The results of a questionnaire sent out to consultant ophthalmologists in the UK, has discovered that there is no one strategy in place for the management of glaucoma in pregnant women.

The results of a questionnaire sent out to consultant ophthalmologists in the UK, has discovered that there is no one strategy in place for the management of glaucoma in pregnant women.

Daniela Vaideanu and Scott Fraser from the Sunderland Eye Infirmary, Tyne and Wear, UK sent out a questionnaire to all consultant ophthalmologists in the UK asking whether they had previous experience of treating pregnant women with glaucoma. If the respondents replied that they had, they were also asked what management they had used, what management they would currently employ and, if they were to use medical treatment, what would be their first choice agent.

Of the 605 questionnaires sent out, 282 were returned. Of the respondents, 26% had previously treated pregnant women with glaucoma. Most (71%) had continued with the therapy that the women were already on. In total, 34%, on observing the situation, decided not to treat. When asked what they would currently do in this scenario, 31% responded that they were unsure and 40% replied that they would continue the current treatment. A total of 45% of respondents said that they would use beta-blockers, should medical treatment be required, whereas 33% said they would use prostaglandins.

On review of the data, the researchers concluded that, although more than a quarter of ophthalmologists have come across the situation, there is currently no optimal strategy in place for dealing with it. They suggest that guidelines be produced based on current knowledge and modified as new evidence appears.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.